Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news


From To
Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK744) that will be taken into efficacy trials to see if it

30 October 2014
Gus Cairns
CHMP Announces Positive Opinion for REZOLSTA™, a New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir and Cobicistat

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a Positive Opinion recommending REZOLSTA™ (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. The CHMP also announced two label extensions for darunavir, a protease inhibitor marketed as PREZISTA® by Janssen.

01 October 2014
Janssen press release
Doctor treats Ebola with HIV drug in Liberia - seemingly successfully

A doctor in rural Liberia inundated with Ebola patients says he's had good results with a treatment he tried out of sheer desperation: an HIV drug. Dr. Gobee Logan has given the drug, lamivudine, to 15 Ebola patients, and all but two survived. That's a 7% mortality rate whereas across West Africa, the virus has killed 70% of its victims.

27 September 2014
Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved by FDA as Individual HIV Drugs

A next-generation boosting agent and an integrase inhibitor joined the growing ranks of approved HIV medications on Sept. 24, when the U.S. Food and Drug Administration (FDA) stamped its seal of approval on Tybost (known generically as cobicistat) and Vitekta (elvitegravir).

26 September 2014
The Body
Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

The studies demonstrated that the single tablet regimen comprising elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF), was non-inferior to Gilead’s Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the proportion of patients with HIV RNA levels (viral load) of less than 50 copies/mL at 48 weeks of therapy. In addition, E/C/F/TAF demonstrated more favorable renal and bone safety compared to Stribild.

25 September 2014
Gilead press release
Gilead's Latest HIV Pill Meets Study Goals

Gilead Sciences Inc. said its new investigational combination pill for HIV met its primary study goals in two late-stage studies, boosting prospects that the biotech company will be able to contain anticipated generic competition to one of its biggest businesses.

24 September 2014
Wall Street Journal
Gilead Sciences: A Preview of Important HIV Drug Study Results

Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.

23 September 2014
The Street
PREZCOBIX™ now available for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. The new treatment option combining a protease inhibitor with a boosting agent reduces the number of pills required to manage HIV.

18 September 2014
First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

Cobicistat-boosted darunavir plus tenofovir alafenamide (TAF) and emtricitabine (FTC) yielded less bone and renal toxicity than darunavir/cobicistat plus tenofovir/emtricitabine (TDF/FTC) in randomized a phase 2 trial.

16 September 2014
Long acting HIV drugs to be developed

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.

15 September 2014
University of Liverpool press release
← First12345...79Next →

Filter by country